Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Prime Medicine Inc
The investment seeks to provide long-term total return. Under normal market conditions, the fund will seek to achieve its investment objective by investing at least 80% of its net assets (including investment borrowings) in U.S. and non-U.S. exchange-traded real estate securities, which includes real estate investment trusts ("REITs"), real estate operating companies ("REOCs") and common stocks or depositary receipts of companies primarily engaged in the real estate industry (collectively, "Real Estate Securities"). It is non-diversified.
IPO Date: October 20, 2022
Sector: Healthcare
Industry: Biotech
Market Cap: $166.74M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.31 | 3.84%
Avg Daily Range (30 D): $0.08 | 5.60%
Avg Daily Range (90 D): $0.10 | 5.16%
Institutional Daily Volume
Avg Daily Volume: .69M
Avg Daily Volume (30 D): 2M
Avg Daily Volume (90 D): 1.5M
Trade Size
Avg Trade Size (Sh.): 116
Avg Trade Size (Sh.) (30 D): 294
Avg Trade Size (Sh.) (90 D): 203
Institutional Trades
Total Inst.Trades: 143
Avg Inst. Trade: $2.2M
Avg Inst. Trade (30 D): $.6M
Avg Inst. Trade (90 D): $.6M
Avg Inst. Trade Volume: .22M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $3.19M
Avg Closing Trade (30 D): $.6M
Avg Closing Trade (90 D): $.6M
Avg Closing Volume: 331.44K
       
News
Mar 19, 2025 @ 6:56 PM
Why Prime Medicine Stock Is Soaring Today
Source: Johnny Rice
Mar 18, 2025 @ 11:00 AM
Prime Medicine Unveils Program for the Treatment o...
Source: N/A
Nov 12, 2024 @ 9:00 PM
Prime Medicine Reports Third Quarter 2024 Financia...
Source: Prime Medicine, Inc.
Nov 6, 2024 @ 9:00 PM
Prime Medicine to Participate in Upcoming Investor...
Source: N/A
Oct 16, 2024 @ 1:45 PM
Why I Keep Buying These 14 Incredible Growth Stock...
Source: George Budwell
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-1.61 $-.4 $-.31
Diluted EPS $-1.61 $-.4 $-.31
Revenue $ 3.85M $ 1.45M $ 2.18M
Gross Profit $ $ $
Net Income / Loss $ -202.01M $ -51.89M $ -42.28M
Operating Income / Loss $ -206.52M $ -52.39M $ -44.22M
Cost of Revenue $ $ $
Net Cash Flow $ -1.72M $ -90.6M $ 64.5M
PE Ratio